Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 24
Titolo Data di pubblicazione Autore(i) File
ACETYLATION INDUCED BY BUTYRATES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA CAN LEAD TO DIFFENTIATION 2002 A. Gozzini; E. Rovida; A Pratesi; P. Dello Sbarba; P Rossi Ferrini; V. Santini
Butyrates as single drug induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. 2003 A.GOZZINI; E.ROVIDA; P.DELLO SBARBA; S.GALIMBERTI; V. SANTINI
INCUBATION OF MURINE ERYTHROLEUKEMIA CELLS IN SEVERE HYPOXIA INDUCES MASSIVE APOPTOSIS PARALLELED BY AKT AND ERK5 CLEAVAGE 2004 S. Giuntoli; E. Rovida; V. Barbetti; A. Gozzini; P. Dello Sbarba
EPIGENETIC MODIFICATIONS IN A T(8;21) ACUTE MYELOID LEUKEMIA CELL LINE CAUSED BY ADMINISTRATION OF THE HDAC INHIBITOR D1 2004 V. Barbetti; E. Rovida; A. Gozzini; S. Giuntoli; V. Santini; P. Dello Sbarba
MAPKS ARE INVOLVED IN THE SURVIVAL AND DIFFERENTIATION OF A T(8;21) ACUTE MYELOID LEUKEMIA CELL LINE AND ARE MODULATED BY THE HDAC INHIBITOR D1 2004 E. Rovida; A. Gozzini; V. Barbetti; S. Giuntoli; V. Santini; P. Dello Sbarba
HDAC INHIBITORS IN COMBINATION WITH HYPOMETHYLATING AGENTS INDUCE SPECIFIC CHROMATIN MODIFICATION AND TRANSCRIPTIONAL ACTIVATION IN CBF/AML CELLS 2005 A. Gozzini; V. Barbetti; E. Rovida; S. Giuntoli; P. Dello Sbarba; V. Santini
SPECIFIC DEGRADATION OF THE AML1-ETO/COREPRESSOR COMPLEX BY A NOVEL ORAL HYDROXAMIC ACID DERIVATIVE 2006 V. Barbetti; A. Gozzini; E. Rovida; P. Dello Sbarba; P. Mascagni; V. Santini
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells 2008 Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V.
Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: Report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo 2011 Alessandrino EP; Angelucci E; Cazzola M; Porta MG; Di Bartolomeo P; Gozzini A; Malcovati L; Pioltelli P; Sica S; Bosi A
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. 2011 Buchi F; Pastorelli R; Ferrari G; Spinelli E; Gozzini A; Sassolini F; Bosi A; Tombaccini D; Santini V
Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO positive leukemia cells 2013 V. Barbetti; A. Gozzini; G. Cheloni; I. Marzi; E. Fabiani; V. Santini; P. Dello Sbarba; E. Rovida
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3. 2014 Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V.
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 2014 VALENCIA MARTINEZ, ANA BELEN; Masala, Erico; Rossi, A.; Martino, A.; Sanna, A.; Buchi, Francesca; Canzian, F.; Cilloni, D.; Gaidano, V.; Voso, M. T.; Kosmider, O.; Fontenay, M.; Gozzini, A.; Bosi, Alberto; Santini, Valeria
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. 2014 Valencia A; Masala E; Rossi A; Martino A; Sanna A; Buchi F; Canzian F; Cilloni D; Gaidano V; Voso MT; Kosmider O; Fontenay M; Gozzini A; Bosi A; Santini V.
Salarin C inhibits maintenance of hypoxia-selected Chronic Myeloid Leukemia progenitor cells 2015 Del Poggetto, E; Tanturli, M; Ben-Califa, N; Gozzini, A; Tusa, I; Cheloni, G; Marzi, I; Cipolleschi, M G; Kashman, Y; Neumann, D; Rovida, E; Dello Sbarba, P
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 2015 Castagnetti, F; Gugliotta, G; Breccia, M; Stagno, F; Iurlo, A; Albano, F; Abruzzese, E; Martino, B; Levato, L; Intermesoli, T; Pregno, P; Rossi, G; Gherlinzoni, F; Leoni, P; Cavazzini, F; Venturi, C; Soverini, S; Testoni, N; Alimena, G; Cavo, M; Martinelli, G; Pane, F; Saglio, G; Rosti, G; Baccarani, M; Bosi, A; Gozzini, A
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. 2016 Bocchia, M; Galimberti, S; Aprile, L; Sicuranza, A; Gozzini, A; Santilli, F; Abruzzese, E; Baratè, C; Scappini, B; Fontanelli, G; Trawinska, Mm; Defina, M; Gozzetti, A; Bosi, A; Petrini, M; Puccetti, L
Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia 2017 Valencia-Martinez, Ana; Sanna, Alessandro; Masala, Erico; Contini, Elisa; Brogi, Alice; Gozzini, Antonella; Santini, Valeria
Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. 2017 Cheloni, G; Tanturli, M; Tusa, I; Desouza, Nh; Shan, Y; Gozzini, A; Mazurier, F; Rovida, E; Li, S; Dello Sbarba, P.
Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. 2018 Masala E, Valencia-Martinez A, Pillozzi S, Rondelli T, Brogi A, Sanna A, Gozzini A, Arcangeli A, Dello Sbarba P, Santini V
Mostrati risultati da 1 a 20 di 24
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile